United States: Amgen Moves To Dismiss Genentech's Misrepresentation Claim

Last Updated: January 10 2018
Article by Christopher Betti and Jennifer Dienes

Amgen paints a different picture as to the bad actor during the parties' negotiations pursuant to the Biologics Price Competition and Innovation Act.

Shortly after Amgen received US Food and Drug Administration (FDA) approval for MVASI® (bevacizumab-awwb), a biosimilar to Genentech's Avastin®, both parties filed competing lawsuits regarding patent infringement, as detailed in a previous LawFlash. Amgen filed a declaratory judgment lawsuit in the US District Court for the Central District of California and Genentech filed a patent infringement lawsuit in the US District Court for the District of Delaware.

In its complaint, Genentech alleged that Amgen contradicted a representation it made during information exchange negotiations (also referred to as the Patent Dance) pursuant to the Biologics Price Competition and Innovation Act (BPCIA). As a result, Genentech sought a declaratory judgment that Amgen not be allowed to market MVASI® until a particular date.1 Amgen moved to dismiss this claim under Federal Rule of Civil Procedure (Rule) 12(b)(6) for failure to state a claim and under Rule 12(b)(1) for lack of subject matter jurisdiction.2

In its motion to dismiss, Amgen contends that Genentech was the bad actor during the Patent Dance negotiations. Amgen accuses Genentech of failing to respond to its detailed noninfringement, invalidity, and/or unenforceability positions disclosed as part of the Patent Dance. Additionally, Amgen contends that, despite having its detailed disclosure of defenses, Genentech intentionally delayed informing Amgen that it still intended to litigate a number of the patents it disclosed pursuant to the Patent Dance. Further, Amgen alleges that Genentech refused to take any action to remove any of its patents or claims from dispute that it previously stated it would not assert. This purportedly caused an impasse and created uncertainty as to which patents and which claims Genentech would assert against Amgen. Because of this, the time period for negotiations under the Patent Dance expired without a final agreement as to the list of patents that would be asserted in an immediate infringement action. As a result, Amgen provided its notice of commercial marketing as required under the BPCIA and filed suit to ascertain the parties' rights and obtain certainty regarding any alleged infringement.

Amgen argues that Genentech failed to state a claim upon which relief could be granted because it is unclear what the underlying federal cause of action is to establish liability or support a declaration of rights that would preclude Amgen from marketing its biosimilar until a specific date. Additionally, Amgen asserts that Genentech failed to plausibly allege that Amgen made a legally binding enforceable representation regarding the date of first commercial marketing. In doing so, Amgen contends that Genentech mischaracterized Amgen's "statement of future intention and the statutory language." According to Amgen, its notice of commercial marketing states that it will begin commercial marketing of MVASI® no earlier than 180 days from October 6, 2017, not that it can begin marketing MVASI® 180 days from October 6, 2017, as Genentech contends. Amgen contends that its notice is in compliance with the BPCIA's commercial marketing notice provision and is consistent with its stated future intent to market MVASI® at a later date. Amgen further argues that there is no evidence of any reliance, detrimental or otherwise, on its stated marketing intention.

It will be interesting to see whether the District of Delaware dismisses Genentech's claim regarding Amgen's allegedly misleading representation. Amgen has certainly provided a number of hooks for the court to do so. However, the parties' competing interpretations of the facts regarding the Patent Dance negotiations suggest that neither party is blameless in causing the breakdown of those negotiations.

Regardless, these litigations show that there remains a substantial amount of uncertainty regarding the interpretation and application of the BPCIA. Parties have demonstrated that they are more than willing to litigate any disputes that arise in order to obtain clarity regarding the metes and bounds of permissible conduct under the BPCIA. Thus, it is likely that the judicial system's work interpreting and clarifying the BPCIA has only just begun.


1 The specifics of this allegation were redacted.

2 Amgen previously moved to dismiss this claim on November 22, 2017. Genentech filed a First Amended and Supplemental Complaint in response, causing Amgen to file another motion to dismiss on December 20, 2017. A redacted version of Amgen's motion to dismiss became available on January 2, 2018.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions